Table 3.
Baseline characteristics for set 2 patients by ChEI and aHTN drug use
| aHTN drug use | No ChEI |
ChEI |
χ2F | P value | ||
|---|---|---|---|---|---|---|
| No | Yes | No | Yes | |||
| N | 40 | 46 | 169 | 174 | ||
| Education (SD) | 13.2 (2.8) | 13.1 (2.6) | 14.8 (3.1) | 13.6 (3.0) | 21.93 | <.0001 |
| Age (SD) | 75.7 (9.8) | 77.6 (6.8) | 72.7 (9.4) | 75.9 (8.0) | 18.25 | <.0001 |
| Baseline MMSE (SD) | 19.4 (4.2) | 22.2 (3.4) | 21.5 (4.3) | 21.2 (4.1) | 10.59 | <.0001 |
| Gender: female (%) | 30 (75.0) | 36 (78.7) | 90 (53.3) | 108 (61.9) | 2.926 | .09 |
| APOEε4 carrier∗ (%) | 23 (57.5) | 23 (50.0) | 105 (62.1) | 100 (57.5) | 1.546 | .238 |
Abbreviations: aHTN, antihypertensive; ChEI, cholinesterase inhibitor; MMSE, Mini-Mental State Examination.
∗
Missing data for APOEε4 genotype: n = 2, both in the ChEI−/aHTN+ group.